A Phase 3 interventional study of Duvelisib and Gemcitabine in Lymphoma, sponsored by SecuraBio. Recruiting at 44 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by SecuraBio · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 237 studies in Lymphoma with a site in France — 33 open to participants now, 54 under way, 11 of them phase 3. Lymphoma · France.
Among the 237 studies in Lymphoma with a site in France, this one is the 85th largest by planned enrollment of the 199 interventional ones that give a count, is one of 7 that started in 2025, is one of 49 in phase 3, reaches primary completion later than 34 of the 53 other live ones, and was the 232nd registered.
3,020 studies on the registry are indexed under Lymphoma; 435 are open to participants now.
Browse Lymphoma studies →33 of the 237 studies in Lymphoma with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–100
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in France, United States, Germany
Ages 18+
Nurix Therapeutics, Inc. · Sites in France, United States, Italy and 2 more countries
Ages 18+
ITM Solucin GmbH · Sites in France, United States, Spain
Ages 24 mo–18 yrs
The Lymphoma Academic Research Organisation · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 347 Lymphoma studies recruiting now, 228 (66%) set no upper age limit and 78 (22%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
237 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 57 · Phase 2 91 · Phase 3 53 · Phase 4 1
First in 1989; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 124 is above the median of 43 across 2,320 interventional studies indexed under Lymphoma.
Median enrollment 110 across the 199 interventional studies, 392 across the 34 observational. Of the 164 that completed or were terminated, 58 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
111 of 237 have an industry lead sponsor. The 10 most frequent:
SecuraBio is the lead sponsor of 25 studies on the registry; 2 are open to participants now.
SecuraBio has 5 studies filed under Lymphoma — fewer than ten, so there is no comparison to draw.
13 of the studies in Lymphoma with a site in France that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT06356129Phase 3CelgeneStudy to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | 2027-08-09 |
| NCT06084936Phase 3Hoffmann-La RocheA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | 2027-08-31 |
| NCT04662255Phase 3Loxo Oncology, Inc.Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | 2027-11 |
| NCT05475925Dren BioA Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | 2026-12 |
Add all 13 to your calendar (.ics) → With an account.
Among the 237 studies in Lymphoma with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH phenotype.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol-defined criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Duvelisib will be administered orally twice daily (BID) in 28-day cycles.
Drug: Duvelisib
Participants will receive the investigator's choice of gemcitabine or bendamustine. The regimen to be used after randomization must be selected by the investigator prior to randomization. Gemcitabine will be administered intravenously (IV) on days 1, 8, and 15 of each 28-day cycle for up to 6 cycles. Bendamustine will be administered IV on days 1 and 2 of each 21-day cycle for up to 6 cycles.
Drug: Gemcitabine · Drug: Bendamustine
oral capsules
solution for intravenous infusion
solution for intravenous infusion
Progression-free Survival (PFS) as assessed by the Independent Review Committee (IRC)
Time frame: Up to 3 years
Overall Survival (OS)
Time frame: Up to 3 years
PFS as assessed by the investigator
Time frame: Up to 3 years
Objective Response Rate (ORR) as assessed by the IRC
Time frame: Up to 3 years
Complete Response Rate (CRR) as assessed by the IRC
Time frame: Up to 3 years
Duration of Response (DOR) as assessed by the IRC
Time frame: Up to 3 years
Proportion of participants who proceed to Stem Cell Transplantation (SCT)
Time frame: Up to 3 years
Investigator-assessed PFS in participants who proceed to SCT
Time frame: Up to 3 years
Number of participants with Adverse Events (AEs)
Time frame: Up to 3 years
Quality of Life (QoL): European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 Score
Time frame: Up to 3 years
QoL: EQ5D Score
Time frame: Up to 3 years
QoL: QLQ-NHL-HG29 Score
Time frame: Up to 3 years
Concentration of Duvelisib and its Metabolites in Blood
Time frame: Day 1 of Cycle 1 and Cycle 2 (predose and 60 minutes postdose)
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Feb 2028, 33 months after the start.
Of 29 industry-sponsored phase 3 interventional studies under Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 69. This study's planned 33 months is below that.
Counting every sponsor, half of 62 studies reached it within 67 months; a quarter within 52 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Duvelisib